Lucy Edwardes Jones

Lucy Edwardes Jones currently serves as a Board Director for Vianautis, Maxion Therapeutics, ENHANC3D GENOMICS, Elasmogen Ltd, and previously for Pathfinder Medical. Additionally, Lucy holds the position of Investor at BGF since July 2020 and was a Board Observer at DefiniGEN from November 2020 to December 2022. Prior experience includes managerial and analytical roles at CIL Management Consultants from August 2015 to July 2020 and an assistant brand manager position at Unilever in the summer of 2013. Lucy Edwardes Jones earned a Bachelor of Arts in History from Durham University and a Master of Science in Russian and East European Studies from the University of Oxford.